Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-04-24Clinical Trial Update: Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder [Phase 3]
Phase 3 trial assessing add-on mirabegron in pediatric patients with refractory overactive bladder completed. Results were posted on 2018-04…
-
CLINICAL_TRIALS trial_result · 2018-03-26Clinical Trial Update: A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India
This clinical trial update reports on a safety and efficacy study of BOTOX (botulinum toxin type A) for urinary incontinence due to neurogen…
-
CLINICAL_TRIALS trial_result · 2018-03-13Clinical Trial Update: Uro-NIRS Clinical Study [NA]
The update reports the completion of the Uro-NIRS clinical study at Weill Medical College of Cornell University for lower urinary tract symp…
-
CLINICAL_TRIALS trial_result · 2018-03-08Clinical Trial Update: Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) [Phase 3]
The ROSETTA Phase 3 trial comparing sacral neuromodulation versus botulinum toxin for refractory overactive bladder has completed and result…
-
CLINICAL_TRIALS trial_result · 2018-03-01Clinical Trial Update: Reproductibility of Cystometry in Multiple Sclerosis Patient
A completed trial from Pierre and Marie Curie University assessed the reproducibility of cystometry measurements in patients with multiple s…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-03-01Clinical Trial Update: Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen [Phase 4]
Phase 4 clinical trial update on baclofen for dysfunctional voiding and lower urinary tract symptoms; study terminated with results posted i…
-
CLINICAL_TRIALS trial_result · 2018-02-28Clinical Trial Update: A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients [Phase 4]
A Phase 4 trial evaluating the combination of mirabegron and solifenacin in adults with overactive bladder; the study is completed with resu…
-
CLINICAL_TRIALS trial_result · 2018-02-28Clinical Trial Update: Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event. [Phase 4]
Phase 4 trial update assessing patient satisfaction after switching to mirabegron for overactive bladder in patients dissatisfied with antim…
-
CLINICAL_TRIALS trial_result · 2018-01-30Clinical Trial Update: Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease [Phase 4]
Phase 4 trial update investigating mirabegron for overactive bladder symptoms in patients with Parkinson's disease.
-
CLINICAL_TRIALS trial_result · 2018-01-19Clinical Trial Update: Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer [Phase 3]
Phase 3 clinical trial investigating solifenacin succinate for urinary toxicity during radiotherapy for prostate cancer was terminated.
-
CLINICAL_TRIALS trial_result · 2018-01-03Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB) [Phase 3]
A Phase 3 trial evaluating the efficacy and safety of Botulinum Toxin Type A for overactive bladder is reported as ongoing with unknown stat…
-
FDA approval · 2017-12-22FDA Approved: OXYBUTYNIN CHLORIDE — Original Application (KVK-Tech, Inc.)
FDA approved the original application for a generic oxybutynin chloride product from KVK-Tech, Inc. for the treatment of overactive bladder.
-
FDA approval · 2017-12-21FDA Approved: OXYBUTYNIN CHLORIDE — Original Application (RISING PHARMA HOLDINGS, INC.)
The FDA approved oxybutynin chloride as a generic drug under an Original Abbreviated New Drug Application submitted by Rising Pharma Holding…
-
CLINICAL_TRIALS trial_result · 2017-12-12Clinical Trial Update: InSite for Over Active Bladder [Phase 4]
Phase 4 results for the InSite device from Medtronic Neuro for overactive bladder and related urinary symptoms have been completed, with res…
-
FDA approval · 2017-12-12FDA Approved: TOLTERODINE TARTRATE — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' tolterodine tartrate as an original application generic, for the treatment of overactive bladder wi…
-
CLINICAL_TRIALS trial_result · 2017-12-11Clinical Trial Update: A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 [Phase 3]
Phase 3 pediatric trial evaluating the safety and effectiveness of solifenacin solution for symptoms of overactive bladder in children/adole…
-
FDA approval · 2017-12-08FDA Approved: DARIFENACIN — Original Application (Alembic Pharmaceuticals Limited)
FDA approved a generic version of darifenacin from Alembic Pharmaceuticals Limited as an original application. Darifenacin is used to treat …
-
CLINICAL_TRIALS trial_result · 2017-12-06Clinical Trial Update: Anticholinergic vs. Botox Comparison Study [Phase 3]
Phase 3 study comparing an anticholinergic therapy to Botox for urge urinary incontinence and overactive bladder has completed and posted re…
-
FDA label_change · 2017-11-12FDA Approved: TOVIAZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental labeling application for TOVIAZ (fesoterodine fumarate) from Pfizer.
-
CLINICAL_TRIALS trial_result · 2017-11-06Clinical Trial Update: OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder [Phase 4]
Phase 4 clinical trial update showing results for onabotulinumtoxinA (Botox) in treating urinary incontinence in patients with overactive bl…
-
CLINICAL_TRIALS trial_result · 2017-10-26Clinical Trial Update: Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder [Phase 2, Phase 3]
The Phase 2/3 trial comparing Bryophyllum Pinnatum, Solifenacin, and placebo for overactive bladder was terminated.
-
FDA approval · 2017-10-24FDA Approved: OXYTROL — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for OXYTROL (oxybutynin) filed by Allergan, Inc. This decision updates the product labeling.
-
FDA approval · 2017-10-23FDA Approved: OXYBUTYNIN CHLORIDE — Original Application (ANI Pharmaceuticals, Inc.)
FDA approved ANI Pharmaceuticals' Original Application for oxybutynin chloride as a generic product for overactive bladder and related urina…
-
CLINICAL_TRIALS trial_result · 2017-10-09Clinical Trial Update: A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) [Phase 3]
This Phase 3 trial assessed whether adding mirabegron to solifenacin improves outcomes for overactive bladder compared with solifenacin alon…
-
CLINICAL_TRIALS trial_result · 2017-10-06Clinical Trial Update: Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
A completed clinical trial evaluates the severity of overactive bladder symptoms in patients after Synergo treatment for bladder cancer.